Skip to content
BLACK BOOK
manufacturer✓ Verified☎ Contact on file

Intellia Therapeutics, Inc.

In Vitro & In Vivo Diagnostic Substances · Cambridge, MA, United States

  1. PrincipalsBirgit C SchultesEVP, Chief Scientific OfficerDavid LebwohlEVP, Chief Medical OfficerEdward J Dulac IIIEVP, Chief Financial Officerand 5 more
  2. CompanyIntellia Therapeutics, Inc.Cambridge, MA, United States
  3. Phone line+1 (857) 285-6200General business
Request a quoteintelliatx.com ↗

Intellia Therapeutics, Inc. is an SEC-registered Nasdaq-listed company (ticker NTLA) classified under SIC 2835: In Vitro & In Vivo Diagnostic Substances.

Capabilities

✓ Pharmaceutical manufacturing
Evidence for each capability
  • Pharmaceutical manufacturing. SIC 2835 — In Vitro & In Vivo Diagnostic Substances — SEC EDGAR company submissions

People 8

Chief executive

John M LeonardPresident and CEO

Chair & board

Fred E CohenDirector (Board)

Finance

Edward J Dulac IIIEVP, Chief Financial Officer
Michael P DubeVP, Chief Accounting Officer

Technology & engineering

Eliana ClarkEVP, Chief Technical Officer

Legal

James BastaEVP, General Counsel
Everyone else on file (2)
Birgit C SchultesEVP, Chief Scientific Officer
David LebwohlEVP, Chief Medical Officer

Supplier profile

Production
Yes

Source timeline

  1. Record created from SEC EDGAR company submissions

    SEC EDGAR company submissions ↗
  2. Birgit C Schultes — EVP, Chief Scientific Officer

    SEC Insider Transactions Data Sets (Forms 3/4/5) ↗
  3. David Lebwohl — EVP, Chief Medical Officer

    SEC Insider Transactions Data Sets (Forms 3/4/5) ↗
  4. Edward J Dulac III — EVP, Chief Financial Officer

    SEC Insider Transactions Data Sets (Forms 3/4/5) ↗
  5. Eliana Clark — EVP, Chief Technical Officer

    SEC Insider Transactions Data Sets (Forms 3/4/5) ↗

Similar makers